Search

Your search keyword '"Greenberg, June"' showing total 27 results
Start Over Author "Greenberg, June"
27 results on '"Greenberg, June"'

1. C5b-9 and MASP2 deposition in skin and bone marrow microvasculature characterize hematopoietic stem cell transplant-associated thrombotic microangiopathy

Author

Elhadad, Sonia, Chadburn, Amy, Magro, Cynthia, Van Besien, Koen, Roberson, Elisha D. O., Atkinson, John P., Terry, Hunter, Greenberg, June, Reid, Whitney, Chapin, John, Copertino, Dennis, Geramfard, Sahar, Rodriguez, Lizamarie Bachier, Orfali, Nina, Gerghis, Usama, Shore, Tsiporah, Mayer, Sebastian, Ahamed, Jasimuddin, and Laurence, Jeffrey

Published
2022
Full Text
View/download PDF

3. Combined Haploidentical and Umbilical Cord Blood Allogeneic Stem Cell Transplantation for High-Risk Lymphoma and Chronic Lymphoblastic Leukemia

Author

Hsu, Jingmei, Artz, Andrew, Mayer, Sebastian A., Guarner, Danielle, Bishop, Michael R., Reich-Slotky, Ronit, Smith, Sonali M., Greenberg, June, Kline, Justin, Ferrante, Rosanna, Phillips, Adrienne A., Gergis, Usama, Liu, Hongtao, Stock, Wendy, Cushing, Melissa, Shore, Tsiporah B., and van Besien, Koen

Published
2018
Full Text
View/download PDF

4. A Phase I Trial of High-Dose Lenalidomide and Melphalan as Conditioning for Autologous Stem Cell Transplantation in Relapsed or Refractory Multiple Myeloma

Author

Mark, Tomer M., Guarneri, Danielle, Forsberg, Peter, Rossi, Adriana, Pearse, Roger, Perry, Arthur, Pekle, Karen, Tegnestam, Linda, Greenberg, June, Shore, Tsiporah, Gergis, Usama, Mayer, Sebastian, Van Besien, Koen, Ely, Scott, Jayabalan, David, Sherbenou, Daniel, Coleman, Morton, and Niesvizky, Ruben

Published
2017
Full Text
View/download PDF

8. Sequential intensive chemotherapy followed by autologous or allogeneic transplantation for refractory lymphoma

Author

Orfali, Nina, primary, Jhanwar, Yuliya, additional, Koo, Calvin, additional, Pasciolla, Michelle, additional, Baldo, Maria, additional, Cuvilly, Edwidge, additional, Furman, Richard, additional, Gergis, Usama, additional, Greenberg, June, additional, Guarneri, Danielle, additional, Hsu, Jing-Mei, additional, Leonard, John P., additional, Mark, Tomer, additional, Mayer, Sebastian, additional, Maignan, Kathleen, additional, Martin, Peter, additional, Opong, Adomah, additional, Pearse, Roger, additional, Phillips, Adrienne, additional, Rossi, Adriana, additional, Ruan, Jia, additional, Rutherford, Sarah C., additional, Ryan, Jessy, additional, Suhu, Grace, additional, Van Besien, Koen, additional, and Shore, Tsiporah, additional

Published
2021
Full Text
View/download PDF

9. Safety and efficacy of plerixafor dose escalation for the mobilization of CD34+ hematopoietic progenitor cells in patients with sickle cell disease: interim results

Author

Boulad, Farid, primary, Shore, Tsiporah, additional, van Besien, Koen, additional, Minniti, Caterina, additional, Barbu-Stevanovic, Mihaela, additional, Fedus, Sylvie Wiener, additional, Perna, Fabiana, additional, Greenberg, June, additional, Guarneri, Danielle, additional, Nandi, Vijay, additional, Mauguen, Audrey, additional, Yazdanbakhsh, Karina, additional, Sadelain, Michel, additional, and Shi, Patricia A., additional

Published
2018
Full Text
View/download PDF

10. Safety and efficacy of plerixafor dose escalation for the mobilization of CD34 + hematopoietic progenitor cells in patients with sickle cell disease: interim results

Author

Boulad, Farid, primary, Shore, Tsiporah, additional, van Besien, Koen, additional, Minniti, Caterina, additional, Barbu-Stevanovic, Mihaela, additional, Fedus, Sylvie Wiener, additional, Perna, Fabiana, additional, Greenberg, June, additional, Guarneri, Danielle, additional, Nandi, Vijay, additional, Mauguen, Audrey, additional, Yazdanbakhsh, Karina, additional, Sadelain, Michel, additional, and Shi, Patricia A., additional

Published
2018
Full Text
View/download PDF

11. Studies of White Cell, Platelet, and Coagulation Activation with Plerixafor Administration in Patients with Sickle Cell Disease

Author

Pham, Petra, primary, Barbu-Stevanovic, Mihaela, additional, Greenberg, June, additional, Guarneri, Danielle, additional, Mitchell, Beau, additional, Minniti, Caterina, additional, Narla, Mohandas, additional, Yazdanbakhsh, Karina, additional, Shore, Tsiporah B., additional, Boulad, Farid, additional, Sadelain, Michel, additional, and Shi, Patricia, additional

Published
2017
Full Text
View/download PDF

12. A Pilot Study of a Sequential Regimen of Intensive Chemotherapy (Bendamustine-Bridge) Followed by Autologous or Allogeneic Transplantation for Refractory Lymphomas

Author

Shore, Tsiporah B., primary, Jhanwar, Yuliya, additional, Baldo, Maria, additional, Cuvilly, Edwidge, additional, Furman, Richard, additional, Gergis, Usama, additional, Greenberg, June, additional, Guarneri, Danielle, additional, Hsu, Jing-Mei, additional, Leonard, John, additional, Mark, Tomer M., additional, Maignan, Kathleen, additional, Martin, Peter, additional, Mayer, Sebastian, additional, Niesvizky, Ruben, additional, Opong, Adomah, additional, Pearse, Roger, additional, Phillips, Adrienne, additional, Rossi, Adriana, additional, Giulino-Roth, Lisa, additional, Ruan, Jia, additional, Rutherford, Sarah, additional, Ryan, Jessy, additional, Suhu, Grace, additional, and van Besien, Koen, additional

Published
2017
Full Text
View/download PDF

14. 293 - A Pilot Study of a Sequential Regimen of Intensive Chemotherapy (Bendamustine-Bridge) Followed by Autologous or Allogeneic Transplantation for Refractory Lymphomas

Author

Shore, Tsiporah B., Jhanwar, Yuliya, Baldo, Maria, Cuvilly, Edwidge, Furman, Richard, Gergis, Usama, Greenberg, June, Guarneri, Danielle, Hsu, Jing-Mei, Leonard, John, Mark, Tomer M., Maignan, Kathleen, Martin, Peter, Mayer, Sebastian, Niesvizky, Ruben, Opong, Adomah, Pearse, Roger, Phillips, Adrienne, Rossi, Adriana, Giulino-Roth, Lisa, Ruan, Jia, Rutherford, Sarah, Ryan, Jessy, Suhu, Grace, and van Besien, Koen

Published
2017
Full Text
View/download PDF

15. Phase 1 study of radiosensitization using bortezomib in patients with relapsed non-Hodgkin lymphoma receiving radioimmunotherapy with131I-tositumomab

Author

Elstrom, Rebecca L., primary, Ruan, Jia, additional, Christos, Paul J., additional, Martin, Peter, additional, Lebovic, Daniel, additional, Osborne, Joseph, additional, Goldsmith, Stanley, additional, Greenberg, June, additional, Furman, Richard R., additional, Avram, Anca, additional, Putman, Ryan, additional, Chapman, Erica, additional, Mazumdar, Madhu, additional, Griffith, Kent, additional, Coleman, Morton, additional, Leonard, John P., additional, and Kaminski, Mark S., additional

Published
2014
Full Text
View/download PDF

16. Phase Ib Study Of Combination Epigenetic Therapy With 5-Azacitidine and Vorinostat In Patients With Relapsed Or Refractory DLBCL

Author

Tang, Tiffany, primary, Martin, Peter, additional, Elstrom, Rebecca L., additional, Ruan, Jia, additional, Furman, Richard R., additional, Garcia, Arcania, additional, Greenberg, June, additional, Rodriguez, Amelyn, additional, Bender, Alison, additional, Lewis, Jessica, additional, Melnick, Ari, additional, Cerchietti, Leandro, additional, and Leonard, John P., additional

Published
2013
Full Text
View/download PDF

17. The Combination Of Palbociclib Plus Bortezomib Is Safe and Active In Patients With Previously Treated Mantle Cell Lymphoma: Final Results Of a Phase I Trial

Author

Martin, Peter, primary, DiLiberto, Maurizio, additional, Mason, Christopher E, additional, Ely, Scott A, additional, Ruan, Jia, additional, Furman, Richard R., additional, Chiron, David, additional, Huang, Xiangao, additional, Madoff, David C, additional, Navi, Jonathan, additional, Lewis, Jessica, additional, Bender, Alison, additional, Rodriguez, Amelyn, additional, Greenberg, June, additional, Coleman, Morton, additional, Chen-Kiang, Selina, additional, and Leonard, John P., additional

Published
2013
Full Text
View/download PDF

18. Phase 1 Study of Radiosensitization Using Bortezomib in Patients with Relapsed Non-Hodgkin's Lymphoma Receiving Radioimmunotherapy

Author

Elstrom, Rebecca L., primary, Leonard, John P., additional, Christos, Paul, additional, Martin, Peter, additional, Lebovic, Daniel, additional, Osborne, Joseph, additional, Goldsmith, Stanley J., additional, Greenberg, June, additional, Furman, Richard R., additional, Ruan, Jia, additional, Putman, Ryan, additional, Chapman, Erica, additional, Mazumdar, Madhu, additional, Griffith, Kent A., additional, Coleman, Morton, additional, and Kaminski, Mark S., additional

Published
2012
Full Text
View/download PDF

19. ClaPD (Clarithromycin, Pomalidomide, Dexamethasone) Therapy in Relapsed or Refractory Multiple Myeloma

Author

Mark, Tomer M, primary, Boyer, Angelique, additional, Rossi, Adriana C, additional, Shah, Manan, additional, Pearse, Roger N, additional, Zafar, Faiza, additional, Pekle, Karen, additional, Tegnestam, Linda, additional, Sacris, Erlinda A, additional, Greenberg, June, additional, Speaker, Stephanie, additional, Jayabalan, David, additional, Ely, Scott A, additional, Coleman, Morton, additional, Chen-Kiang, Selina, additional, and Niesvizky, Ruben, additional

Published
2012
Full Text
View/download PDF

20. A Novel Sequential Treatment Utilizing CPX-351 As Salvage Chemotherapy Followed by a Reduced Intensity Conditioning Allogeneic Stem-Cell Transplantation for Patients with Refractory Leukemia

Author

Gergis, Usama, primary, Roboz, Gail J., additional, Ritchie, Ellen, additional, Scandura, Joseph M., additional, Carlson, Karen-Sue B., additional, Shore, Tsiporah B., additional, Mayer, Sebastian, additional, Mark, Tomer M, additional, Pearse, Roger N, additional, Greenberg, June, additional, Curcio, Tania J, additional, Ippoliti, Cindy, additional, McKenna, Marshall, additional, and Feldman, Eric J, additional

Published
2011
Full Text
View/download PDF

21. Phase 1 Study of Radiosensitization Using Bortezomib in Patients with Relapsed Non-Hodgkin's Lymphoma Receiving Radioimmunotherapy,

Author

Elstrom, Rebecca, primary, Leonard, John P., additional, Goldsmith, Stanley J., additional, Christos, Paul, additional, Martin, Peter, additional, Osborne, Joseph, additional, Lebovic, Daniel, additional, Abdallah, Ramsey, additional, Greenberg, June, additional, Furman, Richard R., additional, Ruan, Jia, additional, Griffith, Kent A., additional, Coleman, Morton, additional, and Kaminski, Mark S., additional

Published
2011
Full Text
View/download PDF

23. Phase 1 study of radiosensitization using bortezomib in patients with relapsed non-Hodgkin lymphoma receiving radioimmunotherapy with 131I-tositumomab.

Author

Elstrom, Rebecca L., Ruan, Jia, Christos, Paul J., Martin, Peter, Lebovic, Daniel, Osborne, Joseph, Goldsmith, Stanley, Greenberg, June, Furman, Richard R., Avram, Anca, Putman, Ryan, Chapman, Erica, Mazumdar, Madhu, Griffith, Kent, Coleman, Morton, Leonard, John P., and Kaminski, Mark S.

Subjects
LYMPHOMA treatment, RADIOIMMUNOTHERAPY, BORTEZOMIB, RADIATION-sensitizing agents, DRUG dosage
Abstract

Radioimmunotherapy (RIT) is effective treatment for indolent non-Hodgkin lymphomas (NHLs), but response durations are usually limited, especially in aggressive NHL. We hypothesized that administration of bortezomib as a radiosensitizer with RIT would be tolerable and improve efficacy in NHL. This phase 1 dose-escalation study evaluated escalating doses of bortezomib combined with 131I-tositumomab in patients with relapsed/refractory NHL. Twenty-five patients were treated. Treatment was well tolerated, with primarily hematologic toxicity. The maximum tolerated dose (MTD) was determined to be 0.9 mg/m2 bortezomib, in combination with a standard dose of 75 cGy 131I-tositumomab. Sixteen patients responded (64%), including 44% complete responses (CRs), with 82% CR in patients with follicular lymphoma (FL). At a median follow-up of 7 months, median progression-free survival was 7 months, and seven of 11 patients with FL remained in remission at a median of 22 months. In conclusion, bortezomib can be safely administered in combination with 131I-tositumomab with promising response rates. [ABSTRACT FROM AUTHOR]

Published
2015
Full Text
View/download PDF

26. A Phase II Study of a Novel Conditioning Regimen of Bendamustine and Melphalan Followed By Autologous Stem Cell Transplant for Patients with Multiple Myeloma

Author

Gomez-Arteaga, Alexandra, Mark, Tomer M, Guarneri, Danielle, Christos, Paul J, Gergis, Usama, Greenberg, June, Hsu, Jingmei, Mayer, Sebastian A., Niesvizky, Ruben, Pearse, Roger, Phillips, Adrienne A., Rossi, Adriana C., Coleman, Morton, Van Besien, Koen, and Shore, Tsiporah B.

Abstract

Introduction

Published
2017
Full Text
View/download PDF

27. Phase 1 study of radiosensitization using bortezomib in patients with relapsed non-Hodgkin lymphoma receiving radioimmunotherapy with 131I-tositumomab.

Author

Elstrom RL, Ruan J, Christos PJ, Martin P, Lebovic D, Osborne J, Goldsmith S, Greenberg J, Furman RR, Avram A, Putman R, Chapman E, Mazumdar M, Griffith K, Coleman M, Leonard JP, and Kaminski MS

Subjects
Adult, Aged, Aged, 80 and over, Antibodies, Monoclonal adverse effects, Antineoplastic Agents adverse effects, Antineoplastic Agents therapeutic use, Bortezomib adverse effects, Chills etiology, Combined Modality Therapy, Disease-Free Survival, Fatigue etiology, Female, Humans, Iodine Radioisotopes adverse effects, Male, Middle Aged, Neoplasm Recurrence, Local, Neutropenia etiology, Radiation-Sensitizing Agents adverse effects, Radiation-Sensitizing Agents therapeutic use, Radioimmunotherapy adverse effects, Remission Induction, Thrombocytopenia etiology, Treatment Outcome, Antibodies, Monoclonal therapeutic use, Bortezomib therapeutic use, Iodine Radioisotopes therapeutic use, Lymphoma, Non-Hodgkin therapy, Radioimmunotherapy methods
Abstract

Radioimmunotherapy (RIT) is effective treatment for indolent non-Hodgkin lymphomas (NHLs), but response durations are usually limited, especially in aggressive NHL. We hypothesized that administration of bortezomib as a radiosensitizer with RIT would be tolerable and improve efficacy in NHL. This phase 1 dose-escalation study evaluated escalating doses of bortezomib combined with 131I-tositumomab in patients with relapsed/refractory NHL. Twenty-five patients were treated. Treatment was well tolerated, with primarily hematologic toxicity. The maximum tolerated dose (MTD) was determined to be 0.9 mg/m2 bortezomib, in combination with a standard dose of 75 cGy 131I-tositumomab. Sixteen patients responded (64%), including 44% complete responses (CRs), with 82% CR in patients with follicular lymphoma (FL). At a median follow-up of 7 months, median progression-free survival was 7 months, and seven of 11 patients with FL remained in remission at a median of 22 months. In conclusion, bortezomib can be safely administered in combination with 131I-tositumomab with promising response rates.

Published
2015
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results